New Zealand markets open in 7 hours 16 minutes

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
15.50+0.12 (+0.78%)
At close: 04:00PM EST
15.50 0.00 (0.00%)
After hours: 04:41PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 424.29M
Enterprise value 544.09M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.33
Price/book (mrq)44.19
Enterprise value/revenue 1.54
Enterprise value/EBITDA -10.33

Trading information

Stock price history

Beta (5Y monthly) 1.41
52-week change 3-57.89%
S&P500 52-week change 314.85%
52-week high 338.43
52-week low 311.60
50-day moving average 316.46
200-day moving average 317.21

Share statistics

Avg vol (3-month) 3925.66k
Avg vol (10-day) 3855.36k
Shares outstanding 529.55M
Implied shares outstanding 6N/A
Float 824.55M
% held by insiders 117.47%
% held by institutions 178.56%
Shares short (30 Dec 2021) 48.41M
Short ratio (30 Dec 2021) 48.72
Short % of float (30 Dec 2021) 441.16%
Short % of shares outstanding (30 Dec 2021) 428.46%
Shares short (prior month 29 Nov 2021) 48.34M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021


Profit margin -30.28%
Operating margin (ttm)-20.95%

Management effectiveness

Return on assets (ttm)-8.33%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)354.33M
Revenue per share (ttm)10.81
Quarterly revenue growth (yoy)16.70%
Gross profit (ttm)307.37M
EBITDA -70.85M
Net income avi to common (ttm)-107.29M
Diluted EPS (ttm)-3.28
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)420.13M
Total cash per share (mrq)14.22
Total debt (mrq)539.93M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.45
Book value per share (mrq)-5.28

Cash flow statement

Operating cash flow (ttm)-61.47M
Levered free cash flow (ttm)-27.72M